Review – Bladder Cancer

The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma

Richard Cathomas a,*, Anja Lorch b, Harman M. Bruins c, Eva M. Compérat d, Nigel C. Cowan e, Jason A. Efstathiou f, Rainer Fietkau g, Georgios Gakis h, Virginia Hernández i, Estefania Linares Espinós j, Yann Neuzillet k, Maria J. Riball l, Matthieu Rouanne m, George N. Thalmann n, Antoine G. van der Heijden o, Erik Veskimäe p, J. Alfred Witjes q, Matthew I. Milowsky r, EAU Muscle-invasive, Metastatic Bladder Cancer Guidelines Panel

a Division of Oncology/Hematology, Cantonal Hospital Grisons, Chur, Switzerland; b Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland; c Department of Urology, Zuyderland Medical Center, Sittard-Geleen-Heerlen, the Netherlands; d Department of Pathology, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Hospital Tenon, Paris, France; e Department of Radiology, Queen Alexandra Hospital, Portsmouth Hospitals University NHS Trust, Portsmouth, UK; f Department of Radiation Therapy, University of Erlangen, Erlangen, Germany; g Department of Urology and Pediatric Urology, University of Würzburg, Würzburg, Germany; h Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain; i Department of Urology, Hospital Universitario La Paz, Madrid, Spain; j Department of Urology, Foch Hospital, University of Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, Suresnes, France; k Department of Urology, Hospital Clinic, University of Barcelona, Barcelona, Spain; l Department of Urology, Inselspital, University Hospital Bern, Bern, Switzerland; m Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; n Department of Urology, Tampere University Hospital, Tampere, Finland; r Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA

Article info

Article history:
Accepted September 28, 2021

Associate Editor:
James Catto

Keywords:
Urothelial carcinoma
Bladder cancer
Metastatic
Systemic therapy
Immunotherapy
Guidelines
European Association of Urology

Abstract

Context: Treatment of metastatic urothelial carcinoma is currently undergoing a rapid evolution.

Objective: This overview presents the updated European Association of Urology (EAU) guidelines for metastatic urothelial carcinoma.

Evidence acquisition: A comprehensive scoping exercise covering the topic of metastatic urothelial carcinoma is performed annually by the Guidelines Panel. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries, resulting in yearly guideline updates.

Evidence synthesis: Platinum-based chemotherapy is the recommended first-line standard therapy for all patients fit to receive either cisplatin or carboplatin. Patients positive for programmed death ligand 1 (PD-L1) and ineligible for cisplatin may receive immunotherapy (atezolizumab or pembrolizumab). In case of nonprogressive disease on platinum-based chemotherapy, subsequent maintenance immunotherapy (avelumab) is recommended. For patients without maintenance therapy, the recommended second-line regimen is immunotherapy (pembrolizumab). Later-line treatment has undergone recent advances: the antibody-drug conjugate enfortumab vedotin demonstrated improved overall survival and the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib appears active in case of FGFR3 alterations.

Conclusions: This 2021 update of the EAU guideline provides detailed and contemporary information on the treatment of metastatic urothelial carcinoma for incorporation into clinical practice.

* Corresponding author. Division of Oncology/Hematology, Cantonal Hospital Grisons, Chur CH-7000, Switzerland. Tel.: +41 81 256 66 46. E-mail address: richard.cathomas@ksgr.ch (R. Cathomas).

https://doi.org/10.1016/j.eururo.2021.09.026
0302-2838/© 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Please cite this article as: R. Cathomas, A. Lorch, H.M. Bruins et al., The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma, Eur Urol (2021), https://doi.org/10.1016/j.eururo.2021.09.026
1. Introduction

Treatment of metastatic urothelial carcinoma (mUC) had remained largely unchanged since pivotal trials published over 20 yr ago set the standard of care for first-line treatment with cisplatin-based combinations demonstrating an overall survival (OS) benefit. In the past few years, this longstanding paradigm has been challenged by several large studies investigating the benefit of immunotherapy using checkpoint inhibitors. Moreover, novel compounds including both targeted therapy and antibody-drug conjugates (ADCs) have successfully been tested and approved in later treatment lines. With many advances in the treatment of urothelial cancer (UC), the European Association of Urology Muscle-invasive and Metastatic Guidelines Panel has decided to publish an updated version of their 2021 treatment recommendations for patients with metastatic disease.

2. First-line systemic therapy for metastatic disease

In general, patients with untreated mUC can be divided into three broad categories: fit for cisplatin-based chemotherapy, fit for carboplatin-based chemotherapy (but unfit for cisplatin), and unfit for any platinum-based chemotherapy.

2.1. Definitions: “fit for cisplatin, fit for carboplatin, and unfit for any platinum-based chemotherapy”

An international survey among bladder cancer (BC) experts [1] was the basis for a consensus statement on how to classify patients unfit for cisplatin-based chemotherapy. At least one of the following criteria must be present: performance status (PS) >1, glomerular filtration rate (GFR) ≤60 ml/min, grade ≥2 audiometric hearing loss, grade ≥2 peripheral neuropathy, or New York Heart Association class III heart failure [2]. Around 50% of patients with BC are not eligible for cisplatin-based chemotherapy [2]. Renal function assessment is of utmost importance for treatment selection. Measuring GFR with radioisotopes (99mTc DTPA or 51Cr-EDTA) is recommended in equivocal cases.

Cisplatin has also been administered in patients with a lower GFR (40–60 ml/min) using different split-dose schedules. The respective studies were mostly small phase I and II trials in different settings (neoadjuvant and advanced disease) demonstrating that the use of split-dose cisplatin is feasible and appears to result in encouraging efficacy [3–5]. However, no prospective randomised trial has compared split-dose cisplatin with conventional dosing.

Most patients who are deemed unfit for cisplatin are able to receive carboplatin-based chemotherapy. However, some patients are deemed unfit for any platinum-based chemotherapy, that is, both cisplatin and carboplatin. Patients are unfit for any platinum-based chemotherapy in case of PS >2, GFR < 30 ml/min, or the combination of PS 2 and GFR < 60 ml/min, since the outcome in this patient population is poor regardless of whether the treatment is platinum based or not [6]. Patients with multiple comorbidities may also be poor candidates for platinum-based chemotherapy. Definitions of platinum eligibility for first-line treatment of mUC are summarised in Table 1.

2.2. First-line chemotherapy in patients fit for cisplatin

Cisplatin-containing combination chemotherapy has been the standard of care since the late 1980s, demonstrating OS of 12–14 mo in different series (for a review, see the study by Bellmunt and Petrylak [7]). Methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) and gemcitabine and cisplatin (GC) achieved survival of 14.8 and 13.8 mo, respectively [8]. Overall response rates (ORRs) were 46% for MVAC and 49% for GC. The lower toxicity of GC [9] compared with standard MVAC has resulted in GC becoming the standard regimen.

Dose-dense MVAC combined with granulocyte colony-stimulating factor is less toxic and more efficacious than standard MVAC in terms of complete response (CR) and 2-yr OS. However, there is no significant difference in median survival between the two regimens [10,11]. Further intensification of treatment using paclitaxel, cisplatin, and gemcitabine (PCG) triple regimen did not result in a significant improvement in OS in the intention-to-treat (ITT) population of a phase III randomised controlled trial (RCT), comparing PCG with GC [12]. Similarly, addition of the angiogenesis inhibitor bevacizumab to GC did not result in OS improvement [13].

### Table 1 – Definitions of platinum eligibility for first-line treatment of metastatic urothelial carcinoma

<table>
<thead>
<tr>
<th>Platinum eligible</th>
<th>Platinum ineligible</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cisplatin eligible</td>
<td>Carboptin eligible</td>
</tr>
<tr>
<td>ECOG PS 0–1</td>
<td>ECOG PS 2 or GFR 30–60 ml/min</td>
</tr>
<tr>
<td>GFR &gt;50–60 ml/min</td>
<td>Or not fulfilling other cisplatin-eligibility criteria</td>
</tr>
<tr>
<td>Audioicmetric hearing loss grade &lt;2</td>
<td>GFR &lt;30 ml/min</td>
</tr>
<tr>
<td>Peripheral neuropathy grade &lt;2</td>
<td>ECOG PS 2 and GFR &lt;50 ml/min</td>
</tr>
<tr>
<td>Cardiac insufficiency NYHA class &gt;II</td>
<td>Comorbidities grade &gt;2</td>
</tr>
</tbody>
</table>

EGFR = growth factor receptor; ECOG = Eastern Cooperative Oncology Group; NYHA = New York Heart Association; PS = performance status.
Disease sites have an impact on long-term survival. Among patients with lymph node–only disease, 20.9% were alive at 5 yr compared with only 6.8% of patients with visceral metastases [8]. In trials with long-term follow-up, approximately 10–15% of patients with mUC are alive at 5 yr and longer, suggesting a sustained benefit from cisplatin-based chemotherapy in a minority of patients [8,11].

Combination chemotherapy demonstrated lower CR rates and acute toxicity was 13.6% with GemCarbo versus 23% with M-CAVI, while the ORR was 42% for GemCarbo and 30% for M-CAVI [6]. Based on these results, the combination of carboplatin and gemcitabine should be considered a standard of care in this patient group.

Combinations of gemcitabine and paclitaxel have been studied as first-line treatment and produced response rates between 38% and 60%, but have never been tested in randomised trials [16–18]. A randomised phase II trial assessed the efficacy and tolerability profile of two vinflunine-based regimens (vinflunine/gemcitabine vs vinflunine/carboplatin). Both regimens showed equal ORR and OS with less haematological toxicity for the combination of vinflunine/gemcitabine [19]. Nonplatinum combination chemotherapy is nevertheless not recommended for first-line use in platinum-eligible patients.

The use of single-agent chemotherapy has been associated with varying response rates. Responses with single agents are usually short, CRs are rare, and no long-term disease-free survival (DFS)/OS has been reported. It is not recommended for first-line treatment of mUC.

2.4. Integration of immunotherapy in the first-line chemotherapy treatment of patients fit for platinum-based treatment (cisplatin or carboplatin)

2.4.1. Immunotherapy combination approaches

In 2020, results of three phase III trials have been published, which investigated the use of immunotherapy in the first-line setting for platinum-eligible patients. The first trial to report was IMvigor130, investigating the combination of the programmed death ligand 1 (PD-L1) inhibitor atezolizumab plus platinum-gemcitabine chemotherapy versus chemotherapy plus placebo versus atezolizumab alone [20]. The primary endpoint of progression-free survival (PFS) benefit for the combination versus chemotherapy alone in the ITT group was reached (8.2 vs 6.3 mo [hazard ratio (HR): 0.82, 95% confidence interval (CI): 0.70–0.96; one-sided \( p = 0.007 \)), while OS was not significant at the interim analysis after a median follow-up of 11.8 mo. The small PFS benefit in the absence of an OS benefit has raised questions of its clinical significance. Owing to the sequential testing design, the comparison of chemotherapy versus atezolizumab alone has not yet been performed formally.

The KEYNOTE 361 study had a very similar design using the PD-1 inhibitor pembrolizumab plus platinum-gemcitabine versus chemotherapy plus placebo versus pembrolizumab alone. The results of the primary endpoints of PFS and OS for the comparison of pembrolizumab plus chemotherapy versus chemotherapy plus placebo in the ITT population showed no benefit for the combination [21].

DANUBE compared the immunotherapy combination (immuno-oncology [IO]-IO) of CTLA-4 inhibitor tremelimumab and PD-L1 inhibitor durvalumab with chemotherapy alone or durvalumab alone [22]. The coprimary endpoint of improved OS for the IO-IO combination versus chemotherapy was not reached in the ITT group, nor was the OS improved for durvalumab monotherapy versus chemotherapy in the PD-L1–positive population.

In conclusion, these three trials do not support the use of the combination of PD-1/L1 checkpoint inhibitors plus chemotherapy or the IO-IO combination as first-line treatment.

2.4.2. Use of first-line single-agent immunotherapy in patients unfit for cisplatin-based chemotherapy

Based on the results of two single-arm phase II trials [23,24], the checkpoint inhibitors pembrolizumab and atezolizumab have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for first-line treatment in cisplatin-unfit patients in case of positive PD-L1 status. PD-L1 positivity for use of pembrolizumab is defined by immunohistochemistry as a combined positive score of ≥10 using the Dako 22C33 platform and for atezolizumab as positivity of ≥5 tumour-infiltrating immune cells using Ventana SP142. Pembrolizumab was tested in 370 patients with advanced UC or mUC ineligible for cisplatin, showing an ORR of 29% and a CR in 7% of patients [23]. Atezolizumab was evaluated in the same patient population in a phase II trial \((n = 119)\) showing an ORR of 23%, with 9% of patients achieving a CR [24].

The trials IMVigor 130, Keynote 361, and DANUBE all included an experimental arm with immunotherapy alone using atezolizumab, pembrolizumab, and durvalumab, respectively [20–22]. No benefit in terms of PFS or OS was found for the use of single-agent immunotherapy compared with platinum-based chemotherapy. The combination of carboplatin/gemcitabine therefore is considered the preferred first-line treatment choice for patients ineligible for cisplatin but eligible for carboplatin.
2.4.3. Switch maintenance with immunotherapy after platinum-based chemotherapy

A randomised phase II trial evaluated switch maintenance treatment with pembrolizumab in patients achieving at least stable disease on platinum-based first-line chemotherapy. The primary endpoint of PFS was met (5.4 vs 3.0 mo, HR: 0.65, p = 0.04) but not the secondary endpoint of OS (22 vs 18.7 mo, HR: 0.91, 95% CI: 0.52–1.59) [25].

The JAVELIN Bladder 100 study investigated the impact of switch maintenance with the PD-L1 inhibitor avelumab after initial treatment with platinum-gemcitabine chemotherapy. Patients achieving at least stable disease or better after four to six cycles of platinum-gemcitabine were randomised to avelumab or best supportive care (BSC). OS was the primary endpoint, which improved to 21.4 mo with avelumab compared with 14.3 mo with BSC (HR: 0.69, 95% CI: 0.56–0.86; p < 0.001). Of patients who discontinued BSC and received subsequent treatment, 53% received immunotherapy. Immune-related adverse events (AEs) occurred in 29% of all patients, and 7% experienced grade 3 complications [26].

In conclusion, maintenance immunotherapy with avelumab is a standard of care for all patients with disease stabilisation on first-line platinum-based chemotherapy.

2.5. Treatment of patients unfit for any platinum-based chemotherapy

Very limited data exist regarding the optimal treatment for this patient population, which is characterised by severely impaired PS (PS >2) and/or severely impaired renal function (GFR <30 ml/min). Historically, the outcome in this patient group has been poor. BSC has often been chosen instead of systemic therapy. Most trials evaluating alternative treatment options to cisplatin-based chemotherapy did not focus specifically on this patient population, thereby making interpretation of data difficult. The FDA (but not EMA) has approved pembrolizumab and atezolizumab as first-line treatment for patients not fit to receive any platinum-based chemotherapy regardless of PD-L1 status, based on the results of two single-arm phase II trials [23,24]. These trials have not reported how many patients were unfit for any platinum-based chemotherapy.

3. Second-line systemic therapy for metastatic disease

3.1. Second-line chemotherapy

Second-line chemotherapy data are highly variable and derive mainly from small single-arm phase II trials apart from a single randomised phase III study. A reasonable strategy has been to rechallenge former platinum-sensitive patients if progression occurred at least 6–12 mo after first-line platinum-based combination chemotherapy. Second-line response rates of single-agent treatment with paclitaxel (weekly), docetaxel, gemcitabine, nab-paclitaxel, oxaliplatin, ifosfamide, topotecan, pemetrexed, lapatinib, gefitinib, and bortezomib have ranged between 0% and 28% in small phase II trials [27,28].

The paclitaxel/gemcitabine combination has shown good response rates in small single-arm studies, but no adequate randomised phase III trial has been conducted [29,30].

Vinflunine was tested in a phase III RCT and compared against BSC in patients progressing after first-line treatment with platinum-based chemotherapy [31]. The results showed a very modest ORR (8.6%), a clinical benefit with a favourable safety profile, and a survival benefit, which was however statistically significant only in the eligible patient population (not in the ITT population).

A randomised phase III trial evaluated the addition of the angiogenesis inhibitor ramucirumab to docetaxel chemotherapy versus docetaxel alone, which resulted in improved PFS (4.1 vs 2.8 mo) and higher response rates (24.5% vs 14%), but no OS benefit was achieved [32,33].

3.2. Second-line immunotherapy for platinum pretreated patients

The immune checkpoint inhibitors pembrolizumab, nivolumab, atezolizumab, avelumab, and durvalumab have demonstrated similar efficacy and safety in patients progressing during, or after, previous platinum-based chemotherapy in phase I, II, and III trials. Pembrolizumab demonstrated a significant OS improvement as second-line treatment in a phase III RCT, leading to EMA and FDA approval. Patients (n = 542) were randomised to receive either pembrolizumab monotherapy or chemotherapy (paclitaxel, docetaxel, or vinflunine). The median OS with pembrolizumab was 10.3 mo (95% CI: 8.0–11.8) versus 7.4 mo (95% CI: 6.1–8.3) with chemotherapy (HR: 0.73, 95% CI: 0.59–0.91, p = 0.002) independent of PD-L1 expression levels [34].

Atezolizumab was the first checkpoint inhibitor approved by the FDA for mUC based on the results of phase I and II trials [35,36]. The phase III RCT IMvigor211, which included 931 patients comparing atezolizumab with second-line chemotherapy (paclitaxel, docetaxel, or vinflunine), did not meet its primary endpoint of improved OS for patients with high PD-L1 expression: 11.1 mo (atezolizumab) versus 10.6 mo (chemotherapy; stratified HR: 0.87, 95% CI: 0.63–1.21, p = 0.41) [37].

The PD-1 inhibitor nivolumab was approved by the FDA based on the results of a single-arm phase II trial (CheckMate 275), enrolling 270 platinum pretreated patients. The primary endpoint of ORR was 19.6%, and OS was 8.74 mo for the entire group [38].

Based on level 1 evidence from a randomised trial, pembrolizumab has emerged in clinic as the preferred standard of care immunotherapy in the second-line setting.

3.3. Side-effect profile of immunotherapy

Checkpoint inhibitors including PD-1 or PD-L1 antibodies and CTLA-4 antibodies have a distinct side-effect profile associated with their mechanism of action, leading to enhanced immune system activity. These AEs can affect any organ in the body, leading to mild, moderate, or severe side effects. The most common organs affected are the skin, gastrointestinal tract, liver, lung, thyroid, and adrenal and pituitary glands. Other systems that may be affected include musculoskeletal, renal, nervous, haematological, ocular, and cardiovascular systems. Any change during immunotherapy treatment should raise a suspicion about a possible relation
to the treatment. The nature of immune-related AEs has very well been characterised and published [39].

The timely and appropriate treatment of immune-related side effects is crucial to achieve optimal benefit from the treatment while maintaining safety. Clear guidelines for side-effect management have been published [40]. Immunotherapy treatment should be applied and supervised by trained clinicians only to ensure early side-effect recognition and treatment. In case of interruption of immunotherapy, rechallenge will require close monitoring for adverse events [41].

4. Integration of novel agents

4.1. Antibody-drug conjugates

The first ADC to report encouraging data was enfortumab vedotin, an ADC targeting Nectin-4, a cell adhesion molecule that is highly expressed in UC conjugated to monomethyl auristatin E (MMAE). A phase II single-arm study (EV-201) in 125 patients previously treated with platinum chemotherapy and checkpoint inhibition showed a confirmed objective response rate of 44%, including 12% CRs [42]. This data led to the accelerated FDA approval for enfortumab vedotin in locally advanced UC or mUC patients who have previously received a PD-1 or PD-L1 inhibitor, and platinum-containing chemotherapy [43]. Another cohort of the same EV-201 trial demonstrated similar promising results in a cohort of 91 patients who were cisplatin ineligible and had received prior immunotherapy [44]. A phase III RCT (n = 608) comparing enfortumab vedotin with single-agent chemotherapy after prior platinum chemotherapy and checkpoint inhibitor immunotherapy demonstrated significant survival benefit of almost 4 mo (12.88 vs 8.97 mo; HR: 0.7, 95% CI: 0.56–0.89) [45]. The most common treatment-related AEs included alopecia (45%), peripheral neuropathy (34%), fatigue (31%, 7.4% grade ≥3), decreased appetite (31%), diarrhea (24%), nausea (23%), and skin rash (16%, 7.4% grade ≥3).

Preliminary results of the combination of enfortumab vedotin and pembrolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced UC/mUC have been reported, resulting in an ORR of 73.3%, with 15.6% CRs [46]. Treatment-related AEs of interest included any rash (48% all grade, 11% grade ≥3) and any peripheral neuropathy (50% all grade, 3% grade ≥3). This combination is currently under investigation in a phase III trial in the first-line setting for platinum-eligible patients (EV-302).

Based on these results, enfortumab vedotin has been approved by the FDA for patients who have received prior platinum-containing chemotherapy and prior immunotherapy with a PD-1 or PD-L1 inhibitor as well as for cisplatin-ineligible patients who have received one or more prior lines of therapy.

Another new and also promising ADC is sacituzumab govitecan, consisting of a humanised monoclonal antibody targeting trophoblast cell surface antigen 2 (Trop-2) conjugated to SN-38, the active metabolite of irinotecan. Sacituzumab govitecan was tested in 113 platinum and immunotherapy pretreated mUC patients and achieved an ORR of 27%, and a total of 77% had a decrease in measurable disease; the median PFS was 5.4 mo and the median OS was 10.9 mo [47]. Side effects consisted of haematological toxicities (neutropenia 34% grade ≥3, febrile neutropenia 10% grade ≥3), fatigue (52%), alopecia (47%), nausea (60%), diarrhoea (65%, 10% ≥ grade 3), and decreased appetite (36%) [47]. Sacituzumab govitecan has received accelerated FDA approval for mUC with prior platinum and immunotherapy pretreatment. Several trials using sacituzumab govitecan as monotherapy or in combinations are on-going.

4.2. FGFR inhibition

Genomic profiling of UC has revealed common potentially actionable genomic alterations, including alterations in fibroblast growth factor receptor (FGFR) [48]. Erdafitinib is a pan-FGFR tyrosine kinase inhibitor and the first FDA-approved targeted therapy for mUC with susceptible FGFR2/3 alterations following platinum-containing chemotherapy. The phase II trial of erdafitinib included 99 patients whose tumour harboured an FGFR3 mutation or FGFR2/3 fusion and who had disease progression following chemotherapy [49]. The confirmed ORR was 40%, and an additional 39% of patients had stable disease. A total of 22 patients had previously received immunotherapy, with only one patient achieving a response; yet the response rate for erdafitinib for this subgroup was 59%. At a median follow-up of 24 mo, the median PFS was 5.5 mo (95% CI: 4.0–6.0) and the median OS was 11.3 mo (95% CI: 9.7–15.2) [49]. Treatment-related AEs of grade ≥3 occurred in 46% of patients. Common AEs of grade ≥3 were hyponatraemia (11%), stomatitis (10%), and asthenia (7%), and 13 patients discontinued erdafitinib due to AEs, including retinal pigment epithelial detachment, hand-foot syndrome, dry mouth, and skin/nail events. In addition to erdafitinib, several other FGFR inhibitors are being evaluated, including infritinib, which has demonstrated promising activity [50]. The increased identification of FGFR3 mutations/fusion has led to several on-going trials with different agents and combination in different disease settings.

5. Current status of predictive biomarkers

The most important advance in recent years has been the recognition of alterations in FGFR3 including mutations and gene fusions as a predictive marker for response to FGFR inhibitors [49]. It is recommended to screen mUC patients ideally at diagnosis of metastatic disease for FGFR3 alterations to plan optimal treatment including trials.

Many efforts have focused on markers for predicting response to immune checkpoint inhibition. PD-L1 expression by immunohistochemistry has been evaluated in many studies with mixed and so far inconclusive results. This may, in part, be related to the use of different antibodies and various scoring systems evaluating different compartments, that is, tumour cells, immune cells, or both. A major limitation of PD-L1 staining relates to the significant proportion of PD-L1-negative patients who respond to immune checkpoint blockade. The predictive value of PD-L1 was not confirmed in large phase III trials.
evaluating the integration of immunotherapy in the first-line setting for mUC [20–22]. At present, the only indication for PD-L1 testing in mUC is dictated by the current FDA and EMA approvals, and relates to the potential use of immune checkpoint inhibitors as first-line monotherapy in patients unfit for cisplatin-containing chemotherapy.

Another biomarker that has been evaluated for predicting response to immunotherapy is high tumour mutational burden (TMB) [51]. Neoantigen burden and TMB have been associated with a response to immune checkpoint blockade in several malignancies. High TMB has been associated with a response to immune checkpoint inhibitors in mUC in small
single-arm trials [35,52], but was not confirmed so far in randomised trials. Other markers that have been evaluated in predicting a response to immune checkpoint inhibitors include molecular subtypes, CD8 expression by immunohistochemistry, and other immune gene cell signatures. Recent work has focused on the importance of stroma, including the role of transforming growth factors in predicting response to immune checkpoint blockade [53,54].

In conclusion, apart from FGFR3 alterations, there are currently no further validated predictive molecular markers that are routinely used in clinical practice.

6. Special situations

6.1. Impact of prior neoadjuvant/adjuvant therapy on treatment sequence

Perioperative systemic treatment is increasingly used in UC, including cisplatin-based chemotherapy in the neoadjuvant setting for BC and adjuvant platinum-based chemotherapy for upper tract UC [55]. Many on-going phase III trials investigate the use of immunotherapy in this setting as well. So far, one trial has reported a significant DFS benefit for adjuvant treatment with nivolumab compared with placebo, whereas one trial reported no significant benefit using atezolizumab versus placebo in the same setting and another trial reported negative findings [56,57]. It is expected that an increased number of patients with mUC would have received pretreatment with platinum and/or immunotherapy agents. No prospective trials have investigated the treatment of such patients. The choice of treatment in these patients depends on the applied perioperative treatment and the time until relapse. If at least 12 mo have passed since the end of perioperative treatment, the same systemic treatment as in treatment-naïve patients is recommended.

6.2. Systemic treatment of metastatic disease with histology other than pure UC

Pure urothelial carcinoma (PUC) represents the predominant histology in over 90% of patients with mUC. Variant histologies (eg, micropapillary, nested, and sarcomatoid) and divergent differentiation (eg, squamous cell carcinoma and adenocarcinoma) can be found in addition to PUC in up to 33% of patients. Such patients were often excluded from large phase II and phase III trials, and therefore the knowledge about the best management of such patients is limited. The respective literature was reviewed recently [58], and an expert Delphi survey and consensus conference provided guidance [59]. In case of predominant PUC, it is recommended to treat patients with mixed histology the same way as patients with PUC histology. Patients with predominant nonurothelial differentiation such as small cell neuroendocrine carcinoma, urachal adenocarcinoma, squamous cell carcinoma, and adenocarcinoma should be treated individually.

7. Summary: treatment algorithm for mUC update 2021

Fig. 1 summarises the treatment algorithm for metastatic BC based on the evidence discussed in this article.

Patients with treatment-naïve mUC are grouped according to platinum eligibility based on clear definitions. In general, first-line treatment consists of platinum-based chemotherapy in which cisplatin is to be preferred to carboplatin. Patients who are cisplatin ineligible but carboplatin eligible should receive carboplatin-gemcitabine combination chemotherapy. In case of positive PD-L1 status, treatment with checkpoint inhibitors (atezolizumab or pembrolizumab) could be an alternative option. Patients unfit for both cisplatin and carboplatin (platinum unfit) can be considered for immunotherapy (FDA approved irrespective of PD-L1 status, EMA approved only for PD-L1 positive) or receive BSC.

In cases of disease stabilisation on platinum-based chemotherapy switch, maintenance treatment with immunotherapy (avelumab) is recommended. Alternatively, patients can be followed closely and receive second-line immunotherapy at the time of progression (pembrolizumab).

It is recommended to determine FGFR mutation status before deciding about second-line treatment. Patients with FGFR3 mutations are candidates for FGFR inhibitor treatment. Enfortumab vedotin therapy is the new standard in case of progression after platinum chemotherapy and immunotherapy but has not yet been approved in Europe. The optimal sequence of novel agents and potential combinations are the subject of many on-going trials. It is generally recommended to treat patients within on-going clinical trials.

Author contributions: Richard Cathomas had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Cathomas, Lorch, Milowsky.
 Acquisition of data: Cathomas, Lorch, Milowsky.
 Analysis and interpretation of data: Cathomas, Lorch, Milowsky.
 Drafting of the manuscript: Cathomas, Lorch, Milowsky.
 Critical revision of the manuscript for important intellectual content: Bruins, Compérat, Cowan, Elstadthiou, Fietkau, Gakis, Hernández, Linares Espinós, Neuillet, Ribal, Rouanne, Thalmann, van der Heijden, Veskimäe, Witjes.
 Statistical analysis: None.
 Obtaining funding: None.
 Administrative, technical, or material support: None.
 Supervision: None.
 Other: None.

Financial disclosures: Richard Cathomas certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Professor Dr. R. Cathomas received personal fees from Roche, Pfizer, MSD, BMS, AstraZeneca, Janssen, Astellas, Bayer, Sanofi Aventis, Debiopharm, Novartis, and Ipsen. Professor Dr. A. Lorch is a principal investigator for phase 2 and 3 trials with Roche, MSD, AstraZeneca, Ipsen, Janssen, Bayer, Novartis, and BMS; is a member of advisory boards for Roche, Novartis, Ipsen, MSD, BMS, and Janssen; receives honoraria for lectures and travel fees from...
Roche, AstraZeneca, Novartis, and Ipsen; and receives travel fees from MSD. Professor Dr. Y. Neuzillet is a consultant for Astellas, AstraZeneca, Bouchara-Recordati, BMS, Ipsen, Janssen, Medac, MSD, Roche, Sanofi Passer, and Sanofi Aventis. Professor Dr. M.J. Ribal receives speaker honoraria from Astellas, Janssen, Ipsen, and Olympus. Professor Dr. G. Gakis is a company consultant for Erbe, Ipsen, Pierre Fabre, Medac, and MSD, and receives research support from IPSEN. Professor Dr. J.A. Witjes receives personal fees as an advisor for Roche, Merck, and BMS. Professor Dr. M.I. Milowsky is a consultant for BioClin Therapeutics and Asieris, and participates in trials from Merck, Acerta Pharma, Roche/Genetech, Bristol Myers Squibb, Seattle Genetics, Astellas, Clovis Oncology, Inivio Pharmaceuticals, AstraZeneca, X4 Pharmaceuticals, Mirati Therapeutics, Boehringer Ingelheim, Constellation Pharma, Jounce Therapeutics, Syndax, Unnocrin Pharma, Medimmune, Cerulean Pharma, and Incyte. Dr. H.M. Bruins, Professor Dr. E.M. Compérat, Dr. N.C. Cowan, Professor Dr. J.A. Efstathiou, Professor Dr. R. Fietkau, Dr. V. Hernández, Dr. E. Linares Espinós, Dr. M. Rouanne, Professor Dr. G.N. Thalmann, Dr. E. Veskimbë, and Dr. A.G. van der Heijden have nothing to declare.

Funding/Support and role of the sponsor: None.

References


